摘要
目的观察顺铂(DDP)、氟尿嘧啶(5-Fu)交替腹腔灌注并ECF(表阿霉素、顺铂、5-氟尿嘧啶)方案治疗原发性腹膜癌腹水控制效果及近期临床疗效、不良反应。方法DDP、5-Fu交替腹腔灌注并ECF方案静脉化疗,21天为一周期,共6~8周期,至少4周期评定疗效。结果15例患者,腹水控制率86.6%;总有效率(RR)86.6%,其中完全缓解(CR)26.6%,部分缓解(PR)60%;主要不良反应为Ⅱ~Ⅲ度骨髓抑制。结论顺铂、氟尿嘧啶交替腹腔灌注并ECF方案治疗原发性腹膜癌腹水控制效果好,近期疗效好,不良反应轻,治疗费用低,可作为原发性腹膜癌的一线治疗方案推广。
Objective To observe the ascites control effects and short-term clinical efficacy and toxicity in the treatment of primary peritoneal carcinoma with cisplatin (DDP), ftuorouracil (5-Fu) alternating ab- dominal perfusion and systemic chemotherapy of ECF (epirubicin, cisplatin, 5- fluorouracil). Methods DDP,5-Fu alternating intraperitoneal perfusion plus ECF program intravenous chemotherapy, one cycle of 21 days for a total of 6-8 cycles, was evaluate at least after 4 cycles. Results In 15 cases, the ascites control rate was 86. 6%, and the total effective rate (RR) 86. 6%, including complete remission (CR) (26. 6 % ), and partial remission (PR) (60 %). The major toxicity wasⅡ-Ⅲ myelosuppression. Conclusion DDP and 5-Fu alternating intraperitoneal perfusion plus ECF in the treatment of primary peritoneal carcinoma has better control of ascites and satisfactory short-term efficacy, slight toxicity light and low- cost. It can be used as first-line treatment programs for primary peritioneal carcinoma.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2010年第1期95-96,共2页
Cancer Research on Prevention and Treatment
关键词
腹膜肿瘤
原发性
腹腔灌注
化疗
Peritoneal tumor
Primary
Peritoneal perfusion
Chemotherapy